Webinar: Structural Basis for HCV RNA Replication and Inhibition by Sofosbuvir

The hepatitis C virus (HCV) can cause chronic liver disease and is the major cause of liver transplantation in the US. Recently, the nucleotide analog inhibitor sofosbuvir was approved by the FDA for treatment of chronic HCV (N. Engl. J. Med. 2013, 368, 34). Sofosbuvir is incorporated into the replicating RNA genome via the viral RNA-dependent RNA polymerase (RdRp) and blocks the incorporation of additional nucleotides thereby inhibiting HCV genomic replication.

This webinar will focus on how HCV RNA polymerase replicates the HCV RNA genome starting with basic biology continuing through Beryllium's structural mechanistic studies with native substrates and nucleotide analog inhibitors such as sofosbuvir.

Learn more or register: http://xtalks.com/HCV-RNA-Replication-and-Inhibition-By-Sofosbuvir.ashx